Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items.
This week, August 14 to 18, 2017, we had thoughts on the following: Straumann (OTCPK:SAUHY) sees a clear advantage in orthodontics; Besponsa's black box blunts Blincyto challenge; Advair generic substitutability and timing take center stage again; Teva (NYSE:TEVA) officially moves into Valeant (NYSE:VRX) territory; Ophthotech (NASDAQ:OPHT) investors celebrate death of Fovista.
Straumann sees a clear advantage in orthodontics
August 18, 2017
